Michael Heidelberger

Michael Heidelberger, an award-winning pioneer in immunochemistry, died June 25 at the age of 103. At the time of his death, he was still a researcher at the New York University Medical Center. Among Heidelberger's many scientific accomplishments was the discovery that antibodies are proteins. Heidelberger was born in New York and completed his undergraduate and graduate education at Columbia University. After earning his Ph.D. in chemistry in 1911, he joined the faculty of the Rockefeller Ins

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Michael Heidelberger, an award-winning pioneer in immunochemistry, died June 25 at the age of 103. At the time of his death, he was still a researcher at the New York University Medical Center. Among Heidelberger's many scientific accomplishments was the discovery that antibodies are proteins.

Heidelberger was born in New York and completed his undergraduate and graduate education at Columbia University. After earning his Ph.D. in chemistry in 1911, he joined the faculty of the Rockefeller Institute. In 1928 he returned to Columbia as the first professor of immunochemistry at the university's College of Physicians and Surgeons, where he remained until he was forced to retire in the mid-1950s.

In 1955, in lieu of opting for a life of leisurely retirement, Heidelberger joined Rutgers University in New Brunswick, N.J., as a visiting professor, a position he maintained for the next nine years. In 1964, he joined the NYU Medical Center ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies